Neural network replicates damaged brain for benefit of neuro patients, AI developers

Researchers at the Salk Institute have used neural network architecture to algorithmically simulate effects of damage to the prefrontal cortexes in patients with neuropsychological impairments. The team believes its findings can inform improved AI development as well as personalized clinical therapies.

Senior study author Terrence Sejnowski, PhD, and colleagues describe their work in a research report published in Proceedings of the National Academy of Sciences.

The scientists focused on getting their AI to mimic the cortical mechanism of “gating,” which controls information flow between neuron clusters to apply existing knowledge to new situations.

Noting that previous attempts to model prefrontal cortex damage produced disappointing results, they explain their system mirrored biological gating by “delegating” different information packets—i.e., artificial neurons—to different subregions of the artificial neural network.

The authors say their system was the first to recreate gating throughout an entire network rather than within discrete subsections.

In an article posted by Salk’s news division, lead author Ben Tsuda, a graduate student pursuing MD and PhD degrees, says the work is yielding a granular view of how the brain is organized. The advance “has implications for both machine learning and gaining a better understanding of some of these diseases that affect the prefrontal cortex,” Tsuda says.

Salk professor Kay Tye, PhD, adds that the human brain is too versatile for even the most sophisticated artificial neural networks to match. A key reason is that the brain can generalize knowledge across varying tasks with dissimilar rules, she explains.  

“In this new work, we show how gating of information can power our new and improved model of the prefrontal cortex,” Tye says.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.